Abstract Library

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4172 Hormonally characterised NF-PanNETs and their clinicopathological features

Introduction: PanNETs show pronounced hormonal heterogeneity. The expression of certain hormones may associate with functional syndromes, but also with histological and genetic features. However, detailed studies of hormonal patterns in PanNETs correlated to morphological and clinical data are lacking.

Conference:

Presenting Author: Moser E

Authors: Moser E, Ito A, Vogel L, Steiger K, Scheidhauer K,

Keywords: Neuroendocrine Tumor, hormonal expression, subtypes, outcome, transcriptional factors,

#3612 Cystatin C may serve as a suitable blood-based biomarker to monitor renal functional decline in patients scheduled for peptide receptor radionuclide therapy

Introduction: Peptide receptor radionuclide therapy (PRRT) for treating somatostatin receptor (SSTR)-positive tumors may be associated with nephrotoxicity.

Conference:

Presenting Author: Hasenauer N

Authors: Hasenauer N, Hartrampf P, Weich A, Higuchi T, Schirbel A,

Keywords: sstr, theragnostics, prrt, renal, nephrotoxicity,

#3195 Peptide Radio Receptor Therapy sensitizes to immunotherapy by increasing expression of checkpoint molecules in in patients with neuroendocrine tumors

Introduction: Peptide Radio Receptor Therapy (PRRT) represents a standard treatment in patients with well-differentiated neuroendocrine tumors (NET G1/G2). Nevertheless, a lack of response is observed in 1/3 of patients after PRRT, suggesting that combination of PRRT with other therapies might increase its efficacy. The combination of PRRT with immune checkpoint inhibitors (ICI) might be promising, since radiation induced cell death can trigger antigen release and lead to activation of the immune system.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hammerich L

Authors: Büttne S, Wiedenmann B, Amthauer H, Tacke F, Roderburg C,

Keywords: neuroendocrine tumor, checkpoint blockade, PRRT, immunotherapy, spectral flow cytometry,

#3164 Automatized hepatic tumor volume analysis of neuroendocrine liver metastases by Gd-EOB MRI - A deep learning model to support multidisciplinary cancer conference decision making

Introduction: Rapid quantification of liver metastasis for diagnosis and follow-up is an unmet medical need in patients with secondary liver malignancies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Xin S, Hartenstein A, Auer T, Dräger F,

Keywords: liver metastases, automatised 3D quantification, deep learning, hepatic tumor load, response evaluation, MRI,